Paul Feuerstadt, MD: Preventing Recurrent C Difficile in Older Adults with Comorbidities
Feuerstadt reviews ACG 2023 data showing live microbiota therapy provides consistent protection against rCDI in one of the most vulnerable patient populations.
British Columbia Paul Feuerstadt Yale University School Of Medicine Drug Administration American College Of Gastroenterology Gastroenterology Center
Source: hcplive.com